biologics therapy in paediatric rheumatology
DESCRIPTION
Biologics Therapy in Paediatric Rheumatology. Rheumatology study day 2014 Alice Chieng. Prevalence of JIA 400:100,000 Mannere et al Incidence of JIA 10- :100,000 Kunamo et al Greater Manchester 100 new cases per year. JIA Diagnosis. History >6 weeksTRANSCRIPT
Biologics Therapy in Paediatric Rheumatology
Rheumatology study day 2014Alice Chieng
• Prevalence of JIA 400:100,000 Mannere et al
• Incidence of JIA 10-:100,000 Kunamo et al
• Greater Manchester 100 new cases per year
JIA Diagnosis
• History >6 weeks• <16 yrs• ≥ 1 joint with evidence of synovitis• Exclusion of infection/ vasculitis
Radiology imaging of JointsSynovial cytologyANA/RF/ HLAB27
JIA Classification• Systemic• Polyarticular RF +ve
RF –ve• Oligoarticularpersistent
extended• Psoriatic arthritis• Enthesitis-related arthritis• Other arthritis
ILAR ( International League of Associations for Rheumatology 2001)
Management
Physiotherapy
Occupational therapist
Rheum Nurse
podiatrist
Clinical Psychologist
orthopaedic
school
growthExercises
Education
Social worker
Medical treatment
Play therapist
Information
career
Transitional
Ophthalmologist
Education
Management
Medical treatment
• Depends on subtypes of JIA• Intra articular steroid injections• DMARD: methotrexate/ sulphasalazine/
leflunomide• Biologics
NICE guidance Failure or intolerance to DMARD by 3 months,
Active joint disease
Core Set Criteria Active Joint Counts
Restricted Joint Counts
Physician Global Assessment Score
Parental VAS
CHAQ
ESR
Which biologics agent should be used?
Current views on pathogenesis of Inflammatory Arthritis- 1
Smolen, J.S. et al., 2007. Lancet, Published online June13
Co- Stimulatory inhibitor- abatacept
Current views on pathogenesis of Inflammatory Arthritis - 2
Smolen, J.S. et al., 2007. Lancet, Published online June13
Anti TNF- EtanerceptInfliximab
Anti IL1 and IL6-AnakinraTocilizumab
Anti-CD20 rituximab
Secretion of IL 1β by monocytes in inflammatory diseases in ‑SOJIA
A possible positive feedback cycle contributes to perpetuation of chronic inflammation in sJIA
Anti IL1 and IL6-AnakinraTocilizumab
Therapeutic Indications - UKEtanercept
(Enbrel)
Rheumatoid arthritis
Ankylosing spondylitis
Psoriatic arthritis
Plaque psoriasis
Polyarticular juvenile idiopathic arthritis
Infliximab
(Remicade)
Rheumatoid arthritis
Ankylosing spondylitis
Psoriatic arthritis
Plaque psoriasis
Crohn’s disease
Ulcerative colitis
Adalimumab
(Humira)
Rheumatoid arthritis
Ankylosing spondylitis
Psoriatic arthritis
Crohn’s disease
Psoriasis
Poly articular Juvenile Idiopathic arthritiswww.emc.medicines.org.uk
Nomenclature
‒ ximab chimeric antibody
‒ zumab humanised antibody
‒ umab human antibody
‒ cept fusion protein
Structure of Etanercept
Human TNF Receptors
Human Antibody
sTNFR:FcActivatedmacrophage Target
cell
Signal
sTNFR
TNFTNFR
sTNFR:Fc
Etanercept - Mode of Action
Etanercept - Mode of Action
Etanercept
Etanercept in Children with polyarticular JRA• 0.4mg/kg twice weekly• ACR 30 pedi- 74%• 82% discontinue coticosteroids or taper below
5mg/day• Safety: 0.12 events per patient year Lovell DJ, Giannini EH et al 2006
Etanercept
• German Etanercept registry- n=1300 66% for 4 years of treatment
• Dutch Registry n=146 38% complete remission
Etanercept
• BNDR Biologics New Drug Registry• N=483• 69% remained on drug after 2 years• 20.7% discontinued- poor efficacy, non
compliance
Etanercept- Adverse Events
• Injection site reaction 39%• URTI 35%• SAE 15% include severe infection• Malignancy and demyelination is rare • New onset uveitis and Cronhs Diseases
Tauber et al 2006, Giannini 2009, Lovell et al 2008
Infliximab• chimeric human–mouse monoclonal
antibody directed against TNF-α• 6 mg/kg at 0, 2 and 4 weeks • 4-8 weeks interval after• apoptosis of cells bearing TNF-α• Not licensed or FDA approved JIA• Crohns >6 yrs
Infliximab
• Lovell Ruperto 2007/ 2010n=122ACR pedi 50/70- 70%/52% at wk 52Infusion reaction 32%
Discontinued 34% Only 30% continue to wk 204
Infliximab
Adverse events• 91% (71/78) reported AE• 1 patient died due to JRA flare with cardiac arrest• infusion reaction 32%• SAE 21.8%
asymptomatic TB in 1 childflares of arthritis, pneumonia
Adalimumab
• Human Anti TNF IgG monoclonal antibody• Dose=24mg/m₂ subcutaneous Injection 2 weekly• Lovell, Ruperto et al 2008 n=171 ACR 30/50/70 monotherapy -74/64/46% ACR 30/50/70 + mtx- 94/91/71
Adalimumab
• Safety: infection 25%• Hypersensitive reaction 6%• Adalumumab antibodies 16%• ACR100 after 2 years: 40%• More effective in uveitis associated with JIA
Tocilizumab
• Recombinant human interleukin 6 receptor antibody
Tocilizumab
• n=56, 8mg /kg 2 wkly infusion• ACR pedi 30/50/70- 91/82/68%• CRP<50 in 2weeks in 86%• Wk 48, 98% still on medication• ACR pedi 30/50/70- 98/94/90%
Yokota et al
Tocilizumab
• Tender Trial- SOJIA n= 88 ACR 30 with no fever 88% ACR70/90- 89%/65% 48% reduction in coticosteroids 33 SAE- 12 attributed by tocilizumab 12 infections- 6 by tocilizumab Ruperto et al 2012
Cherish Trial for poly JIA
Anakinra• Anti IL 1 receptor antagonist
• Lequerre et al 2008 in SOJIAn=20, Duration 6 monthsDose 1-2mg/kg/dayACR paed 50 in 20% AE in 4 patients with severe skin reaction, infection
Anakinra
• IL-1 receptor antagonist• 1–2 mg/kg (max 100 mg daily) by SC• Rosellini et al n=80 SOJIA, poly and oligo 73% responded SOJIA, ACR 30/50- 55/30%• Anajis Trial n=24, placebo/anakinra 67% responded
Rilonacept
• IL-1 R/IL1RacP/Fc fusion protein• Gianinni et al n=9 ACR 50 at 2/4 wks-55/78% sustained at 24 months 2 MAS• On going double blind placebo trial
Abatacept (CTLA4-Ig)A receptor immunoglobulin fusion protein
Adapted from Kremer, J.M., 2004. Rheum Dis Clin N Am, 30, pp. 381–391
Abatacept
• Phase III double blind withdraw trial in Poly JIA• 10 mg/kg IV 4 weekly, n=199• ACR 30/50/70 in 64%/50%/28% achieved• SAE: 6, one ALL, 2 flares of arthritis, joint wear,
Varicella Zoster, ovarian cyst• AE: headache and nausea
Safety with anti TNF• Minor URTI most common• TB reported in infliximab and adalimumab• Demyelinating disease, uveitis, IBD rare• Drug induced lupus rare• Malignancy- 48 reported by FDA88% also received immuno-suppressiveLymphoma, leukaemia, melanoma and solid tumour
Malignancies• Rheumatic conditions (20 cases in total, of which 5 are associated with infliximab, 14 with etanercept and 1 with adalimumab, and includes the conditions: JIA, 15 cases; ankylosing spondylitis, 3 cases; psoriatic
arthritis, 1 case; sarcoidosis, 1 case)
• Other conditions (28 cases in total, of which 26 are associated with infliximab, 1 with etanercept and 1 with adalimumab, and includes the conditions: Crohn disease, 21 cases; ulcerative colitis, 4 cases; in utero exposure, 2 cases; unknown, 1 case)
Hashkets 2010 Nature
• Hepatosplenic T-cell lymphoma* (10 cases)• Non-Hodgkin lymphoma (7 cases)• Hodgkin lymphoma (6 cases)• Leukemia (6 cases)• Malignant melanoma (3 cases)• Thyroid cancer (3 cases)• Basal cell carcinoma, lymphoma with acute myeloid leukemia, leiomyosarcoma, nephroblastoma, renal cell carcinoma, liver cancer, metastatic hepatocellular carcinoma, malignant mastocytosis, neuroblastoma, colorectal cancer, yolk-sactumor, myelodysplasia, bladder cancer (1 case each)
Types of malignancy
Long Term Safety
• British Society for Paediatric and Adolescent Rheumatology Biologic and New Drug Registry for JIA
• All children on etanercept are on the national registry
Summary
• High cost with £8000 to £15,000 per year per patient
• Accessibility is variable in UK• Well tolerated • Transition to adults• Long term safety